Android app on Google Play

AVEO Pharma (AVEO) Says Partner Astellas Won't Submit Tivozani to EMA, Won't Fund Future Trials

May 23, 2013 4:25 PM EDT Send to a Friend
AVEO Pharmaceuticals (NASDAQ: AVEO) said it was informed by its partner, Astellas Pharma Inc., that Astellas no longer intends to submit a Marketing Authorization Application to the European Medicines Agency for tivozanib for the treatment of patients with advanced renal cell carcinoma. Astellas also informed the Company that it does not intend to fund any future trial(s) in RCC under its strategic collaboration with the Company.

The Company is currently evaluating the effect of Astellas’ decision on the clinical and regulatory path forward for tivozanib in RCC.




You May Also Be Interested In


Related Categories

FDA

Add Your Comment